Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yu-Wen,Zhou

第一单位： Department of Colorectal Cancer, West China Hospital, Sichuan University, Chengdu, China.

作者： Yu-Wen,Zhou ^[1] ; Xin,Zhao ^[1] ; Lu,Ni ^[2] ; Peng,Cao ^[1] ; Wei-Bing,Leng ^[1] ; Qing,Zhu ^[3] ; Hong-Feng,Gou ^[3] ; Jiao,Zhang ^[4] ; Xiao-Fen,Li ^[3] ; Meng,Qiu ^[5]

作者单位： Department of Colorectal Cancer, West China Hospital, Sichuan University, Chengdu, China. ^[1] Department of Oncology, Mianyang Central Hospital, Sichuan Province, China. ^[2] Department of Abdominal Oncology, Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan Province, China. ^[3] Genecast Biotechnology Co., Ltd., 88 Danshan Road, Xidong Chuangrong Building, Suite C, 1310-1318, Xishan District, Wuxi City, Jiangsu 214104, China. ^[4] Department of Colorectal Cancer, West China Hospital, Sichuan University, Chengdu, China. Electronic address: qiumeng@hotmail.com. ^[5]

关键词 Cetuximab ctDNA mCRC

主题词人类(Humans);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);结直肠肿瘤(Colorectal Neoplasms);结肠肿瘤(Colonic Neoplasms);直肠肿瘤(Rectal Neoplasms);突变(Mutation);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols)

DOI 10.1016/j.intimp.2024.111887

PMID 38503018

发布时间 2024-04-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交